NeuroVive – Capital Markets Day today at 1:30 p.m. CEST/7:30 a.m. EST.

Lund, Sweden, 9 October 2019NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), holds today, on October 9, 2019, a Capital Markets Day for analysts, investors and media. The program includes an overview of the company's operations and strategy with deeper descriptions of the key projects, the company's external collaborations and the regulatory path towards market approval. Furthermore, an overview is made of the commercial potential of the projects as well as the progress of business development work. 

The day will start with registration from 1:30 p.m. CEST. The program starts at 2:00 p.m. CEST and ends with refreshments and mingle at 5:00 p.m. CEST. The Capital Markets Day will take place at the IVA Conference Center’s Wallenberg Hall at Grev Turegatan 16 in Stockholm.

Agenda:

2:00 p.m Welcome by Moderator Lars Frick and CEO Erik Kinnman.

2:05 p.m Magnus Persson - Associate Professor in physiology, private equity investor and Director of the Board - gives his view of why investments in pharmaceutical development within rare diseases are highly interesting.

2:30 p.m Dr Amel Karaa – Massachusetts General Hospital - international expert in primary mitochondrial diseases, describes the unmet medical need and the research development within the field.

3:00 p.m CEO Erik Kinnman presents NeuroVive’s updated strategy, the portfolio, and describes the background.

3:30 p.m Coffee break: Take the opportunity to ask questions.

4:00 p.m CMO Magnus Hansson and CSO Eskil Elmér give a closer description of the company’s central projects and the external collaborations.

4:30 p.m Matilda Hugerth – Director Clinical & Regulatory Affairs - describes orphan drugs and their regulatory path to market.

5:00 p.m Conclusions followed by mingle and refreshments.

The Capital Markets Day will be moderated by Lars Frick of the equities publication Börsveckan. The written presentations will be in English, and the lectures will mainly be held in Swedish.

The program will be available on NeuroVive’s website after the event. There will also be a live webcast via https://tv.streamfabriken.com/neurovive-cmd-2019.

The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 9 October 2019.

For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/ 

About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury is another clinical phase project. The R&D portfolio also consists of projects for mitochondrial myopathy, NASH and cancer. NeuroVive’s ambition is to take drugs for rare diseases through clinical development and all the way to market, with or without partners. For projects for common indications the goal is out-licensing in preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licensed to Fortify Therapeutics, a BridgeBio company, for the development of a local treatment of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).